Cyclafem 7/7/7

Endometriosis, Low Testosterone, Osteoporosis + 16 more
Treatment
20 Active Studies for Cyclafem 7/7/7

What is Cyclafem 7/7/7

NorethisteroneThe Generic name of this drug
Treatment SummaryNorethisterone, also known as norethindrone, is a synthetic form of the hormone progesterone. It is used to treat menstrual irregularities, endometriosis, and as a form of contraception. It was first created in 1951 in Mexico City and was not used as a contraceptive until 1962. Norethisterone has a greater potency than natural progesterone and is combined with estrogen derivatives for various hormone replacement therapies.
Neconis the brand name
image of different drug pills on a surface
Cyclafem 7/7/7 Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Necon
Norethisterone
1967
347

Effectiveness

How Cyclafem 7/7/7 Affects PatientsNorethisterone is a pill taken to prevent pregnancy or treat hormone-related issues like menopause symptoms and endometriosis. It works like the hormone progesterone but is much stronger. Norethisterone affects the cervix, uterus, and hormones that control the development of eggs. There is a slight higher chance of developing breast cancer when taking this pill, so it is important to regularly check your breasts for any lumps or masses.
How Cyclafem 7/7/7 works in the bodyNorethisterone works mainly by thickening the cervical mucous and making the uterus unfriendly to implantation. It also suppresses the release of hormones from the brain to prevent ovulation and the development of a corpus luteum. In hormone replacement therapy, norethisterone prevents endometrial growth. It has a low affinity for other hormone receptors, though it may cause adverse effects such as acne due to its mild activity at the androgen receptor.

When to interrupt dosage

The prescribed portion of Cyclafem 7/7/7 is contingent upon the recognized affliction, including Atrophic, Fracture and Hormone Replacement Therapy. The quantity of dosage is contingent upon the mode of delivery (e.g. Oral or Tablet) delineated in the table beneath.
Condition
Dosage
Administration
Osteoporosis, Postmenopausal
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Intramuscular; Oral; Topical, Capsule - Oral, Capsule
Hot flashes
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Intramuscular; Oral; Topical, Capsule - Oral, Capsule
hypoestrogenism
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Intramuscular; Oral; Topical, Capsule - Oral, Capsule
Endometriosis
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Intramuscular; Oral; Topical, Capsule - Oral, Capsule
Atrophic
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Intramuscular; Oral; Topical, Capsule - Oral, Capsule
Osteoporosis
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Intramuscular; Oral; Topical, Capsule - Oral, Capsule
Fracture
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Intramuscular; Oral; Topical, Capsule - Oral, Capsule
Estrogen Deprivation Symptoms
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Intramuscular; Oral; Topical, Capsule - Oral, Capsule
Birth Control
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Intramuscular; Oral; Topical, Capsule - Oral, Capsule
Therapeutic procedure
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Intramuscular; Oral; Topical, Capsule - Oral, Capsule
Low Testosterone
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Intramuscular; Oral; Topical, Capsule - Oral, Capsule
Menopause
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Intramuscular; Oral; Topical, Capsule - Oral, Capsule
Oral Contraceptives
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Intramuscular; Oral; Topical, Capsule - Oral, Capsule
Endometriosis
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Intramuscular; Oral; Topical, Capsule - Oral, Capsule
Primary Ovarian Insufficiency
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Intramuscular; Oral; Topical, Capsule - Oral, Capsule
Hormonal Contraception
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Intramuscular; Oral; Topical, Capsule - Oral, Capsule
female castration
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Intramuscular; Oral; Topical, Capsule - Oral, Capsule
Hormone Replacement Therapy
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Intramuscular; Oral; Topical, Capsule - Oral, Capsule
Vasomotor System
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Intramuscular; Oral; Topical, Capsule - Oral, Capsule

Warnings

Cyclafem 7/7/7 Contraindications
Condition
Risk Level
Notes
Liver Diseases
Do Not Combine
Thrombophilia
Do Not Combine
Vaginal Hemorrhage
Do Not Combine
Malignant Neoplasms
Do Not Combine
Benign hepatic neoplasm
Do Not Combine
Breast Cancer
Do Not Combine
Thromboembolism
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Norethisterone may interact with Pulse Frequency
There are 20 known major drug interactions with Cyclafem 7/7/7.
Common Cyclafem 7/7/7 Drug Interactions
Drug Name
Risk Level
Description
Astemizole
Major
The metabolism of Astemizole can be decreased when combined with Norethisterone.
Axitinib
Major
The metabolism of Axitinib can be decreased when combined with Norethisterone.
Cabazitaxel
Major
The metabolism of Cabazitaxel can be decreased when combined with Norethisterone.
Clomipramine
Major
The metabolism of Clomipramine can be increased when combined with Norethisterone.
Copanlisib
Major
The metabolism of Copanlisib can be decreased when combined with Norethisterone.
Cyclafem 7/7/7 Toxicity & Overdose RiskThe lowest toxic dose of oral contraceptives in mice is 6g/kg and in women is 42mg/kg. There have not been any serious issues reported from taking too much oral contraceptives, even if children have ingested them. Symptoms of overdose may include nausea and vomiting.
image of a doctor in a lab doing drug, clinical research

Cyclafem 7/7/7 Novel Uses: Which Conditions Have a Clinical Trial Featuring Cyclafem 7/7/7?

160 active trials are presently examining the potential of Cyclafem 7/7/7 in providing Birth Control, alleviating Atrophic Vaginitis and increasing Low Testosterone levels.
Condition
Clinical Trials
Trial Phases
Birth Control
22 Actively Recruiting
Not Applicable, Phase 3, Phase 4, Early Phase 1, Phase 2
Oral Contraceptives
1 Actively Recruiting
Not Applicable
Endometriosis
27 Actively Recruiting
Early Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4
Osteoporosis
27 Actively Recruiting
Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2
Low Testosterone
6 Actively Recruiting
Phase 4, Phase 2, Phase 1
Endometriosis
2 Actively Recruiting
Phase 4, Not Applicable
Hot flashes
19 Actively Recruiting
Not Applicable, Phase 4, Phase 2, Early Phase 1, Phase 3
Estrogen Deprivation Symptoms
0 Actively Recruiting
Osteoporosis, Postmenopausal
0 Actively Recruiting
female castration
0 Actively Recruiting
Atrophic
4 Actively Recruiting
Phase 4, Not Applicable
Hormone Replacement Therapy
0 Actively Recruiting
Hormonal Contraception
0 Actively Recruiting
hypoestrogenism
1 Actively Recruiting
Phase 4
Fracture
0 Actively Recruiting
Vasomotor System
0 Actively Recruiting
Primary Ovarian Insufficiency
0 Actively Recruiting
Therapeutic procedure
0 Actively Recruiting
Menopause
0 Actively Recruiting

Cyclafem 7/7/7 Reviews: What are patients saying about Cyclafem 7/7/7?

5Patient Review
8/3/2014
Cyclafem 7/7/7 for Birth Control
This medication has been extremely effective for me. I have very light periods and no abdominal cramping whatsoever.
3.7Patient Review
9/9/2015
Cyclafem 7/7/7 for Birth Control
For the last two months, I've been spotting with this pill. It's not a lot but its irritating to come off your period and still be bleeding after the fact. I've been on this pill for quite some time and and it just started doing this a few months ago. What's going on!
2.7Patient Review
9/7/2011
Cyclafem 7/7/7 for Painful Periods
I've been switched to this generic form of Ortho-Novum 7/7/7, and I have not had a good experience. I've had more pain, longer periods, earlier start dates, calf pain, and dehydration. I did fine on two other generic forms.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about cyclafem 7/7/7

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does Pirmella 777 cause weight gain?

"The most common side effects reported were headaches, nausea, menstrual cramps, breast tenderness, abdominal pain, mood changes, acne, irregular uterine bleeding, and weight gain."

Answered by AI

What is Ortho-Novum 777 used for?

"Ortho-Novum 7/7/7 is a combination birth control pill containing female hormones that prevent ovulation."

Answered by AI

Is Nortrel 777 a good birth control?

"Nortrel 7/7/7 is used to treat Birth control. However, it has received mostly negative reviews, with an average rating of 2.8 out of 10. Only 12% of reviewers reported a positive experience, while 76% had a negative experience."

Answered by AI

What kind of birth control is Cyclafem?

"Cyclafem™ 1/35 is a combined oral contraceptive containing the progestational compound norethindrone and the estrogenic compound ethinyl estradiol."

Answered by AI

Clinical Trials for Cyclafem 7/7/7

Image of Goldring Center for High Performance Sport in Toronto, Canada.

Menstrual Cycle vs. Birth Control Pills for Protein Metabolism

18 - 40
Female
Toronto, Canada
The muscles of the body are constantly breaking down old proteins and building new ones. These two processes, protein breakdown and protein synthesis, together are known as protein turnover. Protein turnover is essential for maintaining healthy muscle. Despite its importance, females have historically been underrepresented in protein metabolism research. A long-standing assumption has been that fluctuations in female sex hormones such as estrogen and progesterone, whether across the natural menstrual cycle or in individuals using oral contraceptives (OCs), make metabolism and training responses too variable to study. Because of this, many researchers have excluded female participants for logistical reasons. Resistance exercise, such as weightlifting, is the most effective way to increase muscle size and strength. Each resistance-training session triggers muscle protein synthesis (MPS), the process by which new muscle proteins are built. Consuming dietary protein or individual amino acids further increases the rate at which new proteins are formed. Over time, higher rates of protein synthesis support muscle growth and the maintenance of other lean tissues in the body. The purpose of this study is to examine how menstrual cycle phases and OC use influence the synthesis of proteins in both muscle tissue and the rest of the body. Improving scientific understanding in this area will support more effective, evidence-based training and nutrition recommendations for females.
Recruiting
Has No Placebo
Goldring Center for High Performance Sport
Image of Erevna Innovations Inc. in Montreal, Canada.

Sculptra + Restylane for Post-Menopausal Skin Concerns

40 - 65
Female
Montreal, Canada
The post-menopausal state is marked by a sharp decline in estrogen, leading to significant structural and functional changes in the skin, including collagen loss, dryness, thinning, and reduced elasticity. To address these concerns, aesthetic injectables products such as Sculptra® Aesthetic (poly-L-lactic-acid \[PLLA- SCA\]) and Restylane Skinboosters®\[HASBV\] (small-particle hyaluronic acid - SP-HA) can be used. PLLA-SCA stimulates collagen production via cellular activation (biostimulator), gradually improving dermal structure. HASBV enhances hydration, elasticity, and skin texture when injected under the skin. Considering that hydration and laxity represent the primary aesthetic concerns in this patient population. Targeted treatment with SP-HA (HASBV) to improve hydration and PLLA-SCA to address laxity have been shown to produce significant clinical outcomes by directly addressing these key dermal deficiencies. This approach forms the basis of the current study.
Phase 4
Recruiting
Erevna Innovations Inc.Andreas Nikolis, MD, PhD
Image of University Hospitals Cleveland Medical Center in Cleveland, United States.

Ketamine for Pelvic Pain

18 - 89
Female
Cleveland, OH
The purpose of this research study is to see if ketamine infusion during surgery can decrease pain after surgery. Ketamine is a medication commonly used as part of anesthesia during surgery and is approved by the US FDA. Patients will be randomized to either receive standard anesthesia with OR without ketamine. The surgical procedure will be the same regardless of which group patients are randomized to. After surgery, patients will be asked to rate their pain in the post-operative observation unit and at their two-week post-operative visit. No additional visits are required for participation in this study. The investigators estimate the surveys will take approximately 10 minutes to complete.
Phase 4
Waitlist Available
University Hospitals Cleveland Medical CenterMorgan Cheeks, MD
Have you considered Cyclafem 7/7/7 clinical trials? We made a collection of clinical trials featuring Cyclafem 7/7/7, we think they might fit your search criteria.Go to Trials
Have you considered Cyclafem 7/7/7 clinical trials? We made a collection of clinical trials featuring Cyclafem 7/7/7, we think they might fit your search criteria.Go to Trials
Image of Alethios, Inc. in San Francisco, United States.

NettleEndo for Endometriosis

22 - 45
Female
San Francisco, CA
The goal of this clinical trial is to learn if a wearable brain stimulation device called NettleEndo can reduce chronic pelvic pain and improve wellbeing in women with endometriosis. The study also aims to assess the safety and usability of the device when used at home over several months. The main questions it aims to answer are: 1. Does at-home transcranial direct current stimulation (tDCS) reduce daily pain intensity in women with endometriosis? 2. Does the device also improve mood and sleep quality? Researchers will compare two groups-one receiving active brain stimulation and one receiving a sham (placebo) stimulation-to see if the active device provides greater improvements in symptoms. Participants will: 1. Use the NettleEndo device at home for 20 minutes per session, five times per week for 12 weeks 2. Be randomly assigned to receive either real or sham stimulation through the device 3. Complete daily and weekly symptom ratings through a mobile app 4. Wear an optional fitness tracker to collect data on sleep, movement, and heart rate variability 5. Be followed for 60 days after completing the intervention to monitor longer-term effects All activities are completed remotely using a smartphone app. Participants can contact the study team with questions at any time. The study is double-blind, meaning neither participants nor the researchers assessing outcomes will know who received active or sham treatment until the end of the trial.
Recruiting
Online Trial
Alethios, Inc.Nirav Shah, MD, MPHSamphire Group, Inc.
Have you considered Cyclafem 7/7/7 clinical trials? We made a collection of clinical trials featuring Cyclafem 7/7/7, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security